JPMorgan Chase & Co. assumed coverage on shares of Immunovant (NASDAQ:IMVT – Free Report) in a research report sent to investors on Tuesday, MarketBeat reports. The brokerage issued an overweight rating and a $51.00 target price on the stock. A number of other research analysts have also recently issued reports on the company. Bank of […]
Rhenman & Partners Asset Management AB grew its holdings in Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 66.1% during the third quarter, Holdings Channel.com reports. The firm owned 166,061 shares of the company’s stock after buying an additional 66,061 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Immunovant were worth $6,375,000 […]
Immunovant, Inc. (NASDAQ:IMVT – Free Report) – Equities research analysts at HC Wainwright raised their FY2028 earnings per share estimates for shares of Immunovant in a research note issued to investors on Tuesday, February 13th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of $2.16 for the year, […]